{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:06:19Z","timestamp":1792760779902,"version":"4.5.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1053\/j.semnuclmed.2026.02.004","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T04:45:34Z","timestamp":1772513134000},"page":"200-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advances and challenges of PET imaging in bladder cancer\u2013An update and future trends"],"prefix":"10.1053","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0015-0597","authenticated-orcid":false,"given":"Esther","family":"Mena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Lindenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Choyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.semnuclmed.2026.02.004_bib0001","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1053\/j.semnuclmed.2026.02.004_bib0002","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: an update","volume":"38","author":"Richters","year":"2020","journal-title":"World J Urol"},{"key":"10.1053\/j.semnuclmed.2026.02.004_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.22","article-title":"Bladder cancer","volume":"3","author":"Sanli","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"19","key":"10.1053\/j.semnuclmed.2026.02.004_bib0004","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder Cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2559.2000.00797.x","article-title":"Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases","volume":"36","author":"Bates","year":"2000","journal-title":"Histopathology"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0006","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.02.004_bib0007","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.02.004_bib0008","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.ejrad.2011.07.018","article-title":"Clinical value of FDG PET or PET\/CT in urinary bladder cancer: a systemic review and meta-analysis","volume":"81","author":"Lu","year":"2012","journal-title":"Eur J Radiol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.02.004_bib0009","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder Cancer, Version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.02.004_bib0010","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","article-title":"Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review","volume":"73","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"issue":"20","key":"10.1053\/j.semnuclmed.2026.02.004_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13206090","article-title":"Pre-hydration and a forced diuresis protocol for (18)F-FDG PET\/CT yielded an optimal effect on primary pelvic malignancies","volume":"13","author":"Hsieh","year":"2024","journal-title":"J Clin Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.02.004_bib0012","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1097\/MNM.0000000000002056","article-title":"Added value of delayed imaging after diuretic injection in evaluation of cases of bladder cancer with PET","volume":"46","author":"Ibrahim","year":"2025","journal-title":"Nucl Med Commun"},{"issue":"8","key":"10.1053\/j.semnuclmed.2026.02.004_bib0013","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s12149-018-1280-x","article-title":"Detectability of residual invasive bladder cancer in delayed (18)F-FDG PET imaging with oral hydration using 500 mL of water and voiding-refilling","volume":"32","author":"Higashiyama","year":"2018","journal-title":"Ann Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.02.004_bib0014","doi-asserted-by":"crossref","first-page":"764","DOI":"10.2967\/jnumed.106.036350","article-title":"18F-FDG PET\/CT delayed images after diuretic for restaging invasive bladder cancer","volume":"48","author":"Anjos","year":"2007","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.02.004_bib0015","first-page":"214","article-title":"Dual phase 18F-fluorodeoxyglucose positron emission tomography\/computed tomography with forced diuresis in diagnostic imaging evaluation of bladder cancer","volume":"32","author":"Yildirim-Poyraz","year":"2013","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"10","key":"10.1053\/j.semnuclmed.2026.02.004_bib0016","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/RLU.0000000000001780","article-title":"Enhanced application of 18F-FDG PET\/CT in bladder cancer by adding early dynamic acquisition to a standard delayed PET protocol","volume":"42","author":"Yoon","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.02.004_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2025.10.010","article-title":"Multiparametric Magnetic Resonance Imaging and Vesical Imaging-reporting and data system (VI-RADS) for bladder cancer diagnosis and staging: a guide for clinicians from the American College of Radiology VI-RADS Steering Committee","author":"Panebianco","year":"2025","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2026.02.004_bib0018","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejrad.2017.07.021","article-title":"Diagnostic performance of MRI for prediction of muscle-invasiveness of bladder cancer: a systematic review and meta-analysis","volume":"95","author":"Woo","year":"2017","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2026.02.004_bib0019","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.urology.2020.07.021","article-title":"Diagnostic accuracy of multiparametric MRI for local staging of bladder cancer: a systematic review and meta-analysis","volume":"145","author":"Cornelissen","year":"2020","journal-title":"Urology"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 Guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2026.02.004_bib0021","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1046\/j.1464-410x.2000.00614.x","article-title":"Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis","volume":"85","author":"Leissner","year":"2000","journal-title":"BJU Int"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102462","article-title":"Metastasis profile and survival outcomes of metastatic non-muscle invasive bladder cancer: a National cancer database analysis","volume":"24","author":"Raja Iyub","year":"2026","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.02.004_bib0023","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.urolonc.2022.01.002","article-title":"Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: a multicenter cohort from the European Association of Urology - Young Academic Urologists","volume":"40","author":"Lonati","year":"2022","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.02.004_bib0024","doi-asserted-by":"crossref","first-page":"W95","DOI":"10.2214\/AJR.17.18481","article-title":"The diagnostic performance of MRI for detection of lymph node metastasis in bladder and prostate cancer: an updated systematic review and diagnostic meta-analysis","volume":"210","author":"Woo","year":"2018","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000488200","article-title":"Diagnostic accuracy of F-18 FDG PET\/CT for preoperative lymph node staging in newly diagnosed bladder cancer patients: a systematic review and meta-analysis","volume":"95","author":"Ha","year":"2018","journal-title":"Oncology"},{"issue":"8","key":"10.1053\/j.semnuclmed.2026.02.004_bib0026","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1007\/s00330-018-5959-0","article-title":"Integrated analysis of (18)F-FDG PET\/CT improves preoperative lymph node staging for patients with invasive bladder cancer","volume":"29","author":"Girard","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2026.02.004_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.565086","article-title":"The role of 18F-FDG PET\/CT in guiding precision medicine for invasive bladder carcinoma","volume":"10","author":"Girard","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.02.004_bib0028","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.urolonc.2021.04.027","article-title":"The role of 18F-FDG PET\/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer","volume":"39","author":"Moussa","year":"2021","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.02.004_bib0029","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/bco2.304","article-title":"Comparing fluorodeoxyglucose positron emission tomography with computed tomography in staging for nodal and distant metastasis in urothelial\/bladder cancer","volume":"5","author":"Al-Zubaidi","year":"2024","journal-title":"BJUI Compass"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.02.004_bib0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1590\/S1677-5538.IBJU.2014.0579","article-title":"Is [F-18]-fluorodeoxyglucose FDG-PET\/CT better than ct alone for the preoperative lymph node staging of muscle invasive bladder cancer?","volume":"42","author":"Uttam","year":"2016","journal-title":"Int Braz J Urol"},{"key":"10.1053\/j.semnuclmed.2026.02.004_bib0031","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12894-015-0080-z","article-title":"PET\/CT versus conventional CT for detection of lymph node metastases in patients with locally advanced bladder cancer","volume":"15","author":"Aljabery","year":"2015","journal-title":"BMC Urol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0032","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1097\/RLU.0000000000001432","article-title":"Prospective pilot study to evaluate the incremental value of PET information in patients with bladder cancer undergoing 18F-FDG simultaneous PET\/MRI","volume":"42","author":"Rosenkrantz","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.02.004_bib0033","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.clgc.2020.02.008","article-title":"Pilot study of [(18)F] fluorodeoxyglucose positron emission tomography (FDG-PET)\/magnetic resonance imaging (MRI) for staging of muscle-invasive bladder cancer (MIBC)","volume":"18","author":"Eulitt","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0034","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ucl.2024.07.011","article-title":"Urologic imaging of the bladder: cancers and mimics","volume":"52","author":"Amirian","year":"2025","journal-title":"Urol Clin North Am"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.02.004_bib0035","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1464-410X.2010.09212.x","article-title":"Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma","volume":"106","author":"Lodde","year":"2010","journal-title":"BJU Int"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.02.004_bib0036","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 Guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"European Urology"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0037","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; Amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.02.004_bib0038","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s11596-013-1103-1","article-title":"Application of 18F-FDG PET\/CT imaging in diagnosing bladder tumor metastasis lesions","volume":"33","author":"Li","year":"2013","journal-title":"J Huazhong Univ Sci Technol"},{"issue":"25","key":"10.1053\/j.semnuclmed.2026.02.004_bib0039","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1200\/JCO.2010.28.7052","article-title":"Clinical value of fluorine-18 2-fluoro-2-deoxy-d-glucose positron emission tomography\/computed tomography in bladder cancer","volume":"28","author":"Apolo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.02.004_bib0040","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.clgc.2023.02.004","article-title":"Added clinical value of (18)F-FDG-PET\/CT to stage patients with high-risk non-muscle invasive bladder cancer before radical cystectomy","volume":"21","author":"van Ginkel","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.02.004_bib0041","doi-asserted-by":"crossref","first-page":"834","DOI":"10.4143\/crt.2014.157","article-title":"Detecting metastatic bladder cancer using (18)F-fluorodeoxyglucose positron-emission tomography\/computed tomography","volume":"47","author":"\u00d6zt\u00fcrk","year":"2015","journal-title":"Cancer Res Treat"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.02.004_bib0042","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00345-016-1772-z","article-title":"The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis","volume":"34","author":"Soubra","year":"2016","journal-title":"World J Urol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2026.02.004_bib0043","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1442-2042.2012.02989.x","article-title":"Clinical value of whole body fluorine-18 fluorodeoxyglucose positron emission tomography\/computed tomography in the detection of metastatic bladder cancer","volume":"19","author":"Yang","year":"2012","journal-title":"Int J Urol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.02.004_bib0044","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bju.12608","article-title":"Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer","volume":"114","author":"Goodfellow","year":"2014","journal-title":"BJU Int"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.02.004_bib0045","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/j.clgc.2016.08.009","article-title":"Pelvic lymph node staging by combined (18)F-FDG-PET\/CT imaging in bladder cancer prior to radical cystectomy","volume":"15","author":"Pichler","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.02.004_bib0046","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clgc.2021.03.002","article-title":"The diagnostic value of FDG-PET\/CT for urachal cancer","volume":"19","author":"Stokkel","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.02.004_bib0047","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.02.004_bib0048","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","author":"Vale","year":"2005","journal-title":"Eur Urol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.02.004_bib0049","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3109\/00365599.2011.609832","article-title":"Prognostic value of lymph-node dissection in patients undergoing radical cystectomy following previous oncological treatment for bladder cancer","volume":"45","author":"Jensen","year":"2011","journal-title":"Scand J Urol Nephrol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.juro.2015.07.085","article-title":"A multi-institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy","volume":"195","author":"Zargar-Shoshtari","year":"2016","journal-title":"J Urol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.02.004_bib0051","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.02.004_bib0052","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.02.004_bib0053","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/bju.16191","article-title":"Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer","volume":"133","author":"Necchi","year":"2024","journal-title":"BJU Int"},{"issue":"7","key":"10.1053\/j.semnuclmed.2026.02.004_bib0054","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/RLU.0000000000004639","article-title":"Predictive value of 18 F-FDG PET\/CT for assessment of tumor response to neoadjuvant chemotherapy in bladder cancer","volume":"48","author":"Ko","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.02.004_bib0055","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/bju.15374","article-title":"Complete metabolic response with [18F]fluorodeoxyglucose-positron emission tomography\/computed tomography predicts survival following induction chemotherapy and radical cystectomy in clinically lymph node positive bladder cancer","volume":"129","author":"Abrahamsson","year":"2022","journal-title":"BJU Int"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.02.004_bib0056","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s11255-017-1637-4","article-title":"FDG-PET\/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy","volume":"49","author":"van de Putte","year":"2017","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.02.004_bib0057","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.02.004_bib0058","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17020232","article-title":"Nuclear medicine and molecular imaging in urothelial cancer: current status and future directions","volume":"17","author":"McDonald","year":"2025","journal-title":"Cancers"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.02.004_bib0059","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s00259-016-3500-8","article-title":"Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET\/CT","volume":"44","author":"Alongi","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.02.004_bib0060","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050700","article-title":"(18)F-FDG PET\/CT and urothelial carcinoma: impact on management and prognosis-a multicenter retrospective study","volume":"11","author":"Zattoni","year":"2019","journal-title":"Cancers"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.02.004_bib0061","first-page":"562","article-title":"Diagnostic evaluation of 18F-FDG PET\/CT imaging in recurrent or residual urinary bladder cancer: a meta-analysis","volume":"17","author":"Xue","year":"2020","journal-title":"Urol J"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.02.004_bib0062","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15112951","article-title":"Assessing the performance of 18F-FDG PET\/CT in bladder cancer: a narrative review of current evidence","volume":"15","author":"Bacchiani","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0063","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/BLC-220036","article-title":"Prospective evaluation of FDG-PET\/CT for on-treatment assessment of response to neoadjuvant or induction chemotherapy in invasive bladder cancer","volume":"9","author":"Einerhand","year":"2023","journal-title":"Bladder Cancer"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0064","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4274\/mirt.galenos.2023.65002","article-title":"The added-value of staging (18)F-FDG PET\/CT in the prediction of overall survival in the patients with bladder cancer","volume":"33","author":"Ates","year":"2024","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.02.004_bib0065","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.clgc.2018.05.008","article-title":"FDG-PET\/CT for assessing the response to neoadjuvant chemotherapy in bladder cancer patients","volume":"16","author":"Soubra","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.02.004_bib0066","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.euf.2020.10.003","article-title":"Incidence and clinical impact of inflammatory fluorodeoxyglucose positron emission tomography uptake after neoadjuvant pembrolizumab in patients with organ-confined bladder cancer undergoing radical cystectomy","volume":"7","author":"Marandino","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.02.004_bib0067","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/bju.15374","article-title":"Complete metabolic response with [(18) F]fluorodeoxyglucose-positron emission tomography\/computed tomography predicts survival following induction chemotherapy and radical cystectomy in clinically lymph node positive bladder cancer","volume":"129","author":"Abrahamsson","year":"2022","journal-title":"BJU Int"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.02.004_bib0068","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040869","article-title":"Quantitative FDG PET assessment for oncology therapy","volume":"13","author":"Hirata","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0069","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.zemedi.2022.09.001","article-title":"Clinical use of positron emission tomography for radiotherapy planning - medical physics considerations","volume":"33","author":"Thorwarth","year":"2023","journal-title":"Z Med Phys"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.02.004_bib0070","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00345-017-2168-4","article-title":"Diagnostic accuracy of C-11 choline and C-11 acetate for lymph node staging in patients with bladder cancer: a systematic review and meta-analysis","volume":"36","author":"Kim","year":"2018","journal-title":"World J Urol"},{"key":"10.1053\/j.semnuclmed.2026.02.004_bib0071","article-title":"The role of non-FDG agents in PET imaging of bladder cancer","author":"Safarian","year":"2025","journal-title":"Semin Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0072","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40644-018-0158-4","article-title":"(11)C-acetate PET\/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial)","volume":"18","author":"Salminen","year":"2018","journal-title":"Cancer Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.02.004_bib0073","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11307-011-0488-0","article-title":"Initial results with (11)C-acetate positron emission tomography\/computed tomography (PET\/CT) in the staging of urinary bladder cancer","volume":"14","author":"Schoder","year":"2012","journal-title":"Mol Imaging Biol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.02.004_bib0074","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1016\/j.ejrad.2012.06.010","article-title":"Prospective evaluation of MRI, (1)(1)C-acetate PET\/CT and contrast-enhanced CT for staging of bladder cancer","volume":"81","author":"Vargas","year":"2012","journal-title":"Eur J Radiol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.02.004_bib0075","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24031935","article-title":"Superiority of [(11)C]methionine over [(18)F]deoxyglucose for PET imaging of multiple cancer types due to the methionine addiction of cancer","volume":"24","author":"Kubota","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.02.004_bib0076","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.21873\/anticanres.17216","article-title":"(11)C]methionine PET vs. [(18)F]Fluorodeoxyglucose PET whole-body imaging to determine the extent of methionine-addiction compared to glucose-addiction of primary and metastatic cancer of the trunk in patients","volume":"44","author":"Sato","year":"2024","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1053\/j.semnuclmed.2026.02.004_bib0077","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2967\/jnumed.121.262426","article-title":"Correlation of (68)Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: interim analysis of a prospective translational exploratory study","volume":"63","author":"Mona","year":"2022","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.02.004_bib0078","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11307-022-01715-3","article-title":"Head-to-head intra-individual comparison of [(68)Ga]-FAPI and [(18)F]-FDG PET\/CT in patients with bladder cancer","volume":"24","author":"Novruzov","year":"2022","journal-title":"Mol Imaging Biol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.02.004_bib0079","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1007\/s00259-024-06595-z","article-title":"(68)Ga]Ga-FAPI-46 PET\/CT for locoregional lymph node staging in urothelial carcinoma of the bladder prior to cystectomy: initial experiences from a pilot analysis","volume":"51","author":"Unterrainer","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.02.004_bib0080","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2967\/jnumed.123.266390","article-title":"Initial experience with (68)Ga-FAP-2286 PET imaging in patients with urothelial cancer","volume":"65","author":"Koshkin","year":"2024","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0081","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41598-019-55013-0","article-title":"Fibroblasts in urothelial bladder cancer define stroma phenotypes that are associated with clinical outcome","volume":"10","author":"Mezheyeuski","year":"2020","journal-title":"Sci Rep"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.02.004_bib0082","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1007\/s00259-025-07239-6","article-title":"(68)Ga-FAPI and (18)F-FAPI PET\/CT for detection of nodal metastases prior radical cystectomy in high-risk urothelial carcinoma patients","volume":"52","author":"Unterrainer","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.02.004_bib0083","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-025-04164-9","article-title":"Nectin-4 expression in upper and lower tract urothelial carcinoma: correlation with early-stage disease and prognostic relevance","author":"Kobayashi","year":"2025","journal-title":"Virchows Arch"},{"issue":"8","key":"10.1053\/j.semnuclmed.2026.02.004_bib0084","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.02.004_bib0085","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0086","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/bju.16901","article-title":"Staging metastatic urothelial cancer with nectin-4 imaging using gallium-68-N188 PET\/CT","volume":"137","author":"Miederer","year":"2026","journal-title":"BJU Int"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0087","article-title":"Translational PET imaging of nectin-4 expression in multiple different cancers with (68)Ga-N188","volume":"65","author":"Zhang","year":"2024","journal-title":"J Nucl Med"},{"issue":"17","key":"10.1053\/j.semnuclmed.2026.02.004_bib0088","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-23-0609","article-title":"First-in-Human study of the Radioligand 68Ga-N188 targeting nectin-4 for PET\/CT imaging of advanced urothelial carcinoma","volume":"29","author":"Duan","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.02.004_bib0089","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.02.004_bib0090","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/s44321-024-00059-5","article-title":"ImmunoPET imaging of Trop2 in patients with solid tumours","volume":"16","author":"Huang","year":"2024","journal-title":"EMBO Mol Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.02.004_bib0091","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1021\/acs.molpharmaceut.8b00062","article-title":"Immuno-PET imaging of (89)Zr labeled anti-PD-L1 domain antibody","volume":"15","author":"Li","year":"2018","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.02.004_bib0092","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"(89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med"},{"key":"10.1053\/j.semnuclmed.2026.02.004_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfa.2025.137332","article-title":"Noninvasive ImmunoPET imaging of PD-L1 expression in non-small cell lung cancer and bladder cancer using [(89)Zr]Zr-DFO-Durvalumab","volume":"723","author":"Huang","year":"2025","journal-title":"Colloids Surf A"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.02.004_bib0094","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/RLU.0000000000006239","article-title":"Noninvasive evaluation of HER2 expression and heterogeneity in urothelial carcinoma on 68Ga-HER2-affibody PET\/CT","volume":"51","author":"Tao","year":"2026","journal-title":"Clin Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2026.02.004_bib0095","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1007\/s00259-025-07142-0","article-title":"Non-invasive assessment of HER2 expression in patients with urothelial carcinoma using [68Ga]Ga-HER2 affibody PET\/CT imaging: preliminary clinical findings","volume":"52","author":"Zou","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.02.004_bib0096","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.humpath.2020.10.006","article-title":"Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Grigg","year":"2021","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0097","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12894-022-01157-7","article-title":"EGFR and PSMA as possible imaging targets of lymph node metastases of urothelial carcinoma of the bladder","volume":"22","author":"van der Fels","year":"2022","journal-title":"BMC Urol"},{"issue":"19","key":"10.1053\/j.semnuclmed.2026.02.004_bib0098","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17193261","article-title":"Beyond visualization: advanced imaging, theragnostics and biomarker integration in urothelial bladder cancer","volume":"17","author":"Albers Acosta","year":"2025","journal-title":"Cancers"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.02.004_bib0099","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.euf.2021.07.016","article-title":"Urothelial carcinoma and prostate-specific membrane antigen: cellular, imaging, and prognostic implications","volume":"8","author":"Tariq","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.02.004_bib0100","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1590\/s1677-5538.ibju.2023.0312","article-title":"Head-to-head comparisons of enhanced CT, 68Ga-PSMA-11 PET\/CT and 18F-FDG PET\/CT in identifying adverse pathology of clear-cell renal cell carcinoma: a prospective study","volume":"49","author":"Chen","year":"2023","journal-title":"Int Braz J Urol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0101","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40644-023-00609-z","article-title":"CT-based deep learning radiomics nomogram for the prediction of pathological grade in bladder cancer: a multicenter study","volume":"23","author":"Song","year":"2023","journal-title":"Cancer Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.02.004_bib0102","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00261-023-04028-3","article-title":"MRI radiomics for predicting poor disease-free survival in muscle invasive bladder cancer: the results of the retrospective cohort study","volume":"49","author":"Fan","year":"2024","journal-title":"Abdom Radiol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.02.004_bib0103","doi-asserted-by":"crossref","first-page":"7215","DOI":"10.1016\/j.acra.2025.08.035","article-title":"AI-driven and traditional radiomic model for predicting muscle invasion in bladder cancer via multi-parametric imaging: a systematic review and meta-analysis","volume":"32","author":"Wang","year":"2025","journal-title":"Acad Radiol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.02.004_bib0104","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1007\/s00330-022-09272-7","article-title":"Predicting muscle invasion in bladder cancer by deep learning analysis of MRI: comparison with vesical imaging-reporting and data system","volume":"33","author":"Li","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2026.02.004_bib0105","doi-asserted-by":"crossref","DOI":"10.1007\/s10278-025-01804-z","article-title":"Handcrafted vs. deep radiomics vs. fusion vs. deep learning: a comprehensive review of machine learning -based cancer outcome prediction in PET and SPECT imaging","author":"Salmanpour","year":"2026","journal-title":"J Imaging Inform Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.02.004_bib0106","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s00330-022-09270-9","article-title":"A machine-learning-based combination of criteria to detect bladder cancer lymph node metastasis on [(18)F]FDG PET\/CT: a pathology-controlled study","volume":"33","author":"Girard","year":"2023","journal-title":"Eur Radiol"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.02.004_bib0107","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1007\/s00259-021-05244-z","article-title":"Convolutional neural networks for PET functional volume fully automatic segmentation: development and validation in a multi-center setting","volume":"48","author":"Iantsen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299826000462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299826000462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:50:20Z","timestamp":1773845420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299826000462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":107,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0001299826000462"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2026.02.004","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances and challenges of PET imaging in bladder cancer\u2013An update and future trends","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2026.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}